A new essay in the journal Aging revisits the scientific legacy of Mikhail “Misha” Blagosklonny, the physician-scientist whose unconventional ideas helped transform debates about why organisms grow old. Published in Volume 18 of Aging on August 6, 2026, the article, titled “Misha Blagosklonny: a life of ideas,” examines the theories, research strategy, and intellectual influence of a scientist who argued that aging may be driven less by passive molecular deterioration than by biological programs that remain active long after their useful period has ended.

Written by David Gems of University College London and Marco Demaria of the European Research Institute for the Biology of Ageing at the University Medical Center Groningen, the essay is not a report of new laboratory experiments. Instead, it analyzes Blagosklonny’s scientific contributions and explains why his conceptual approach continues to attract attention across aging biology, cancer research, evolutionary physiology, and medicine. The authors portray him as a highly original thinker who used existing experimental evidence to construct new mechanistic explanations for age-related decline.

Blagosklonny began his career as a physician and experimental scientist before establishing an influential research program in oncology and gerontology in the United States. His work connected cancer biology with the biology of aging, particularly through the mechanistic target of rapamycin, or mTOR, a central nutrient-sensing pathway. mTOR regulates protein synthesis, cell growth, metabolism, and proliferation. It is essential during development and reproductive maturity, but persistent activation later in life can promote pathological growth, cellular stress, and senescence, a state in which cells remain metabolically active but permanently stop dividing.

This observation became a foundation of Blagosklonny’s hyperfunction theory of aging. According to the theory, many age-related disorders arise because biological processes that are beneficial early in life continue operating after growth and development are complete. The result is not simply a body wearing down from accumulated damage, but a system in which normal growth-promoting activity becomes excessive and harmful. In this framework, aging is linked to the overactivity of pathways involved in development, metabolism, tissue growth, and reproduction.

A key concept in Blagosklonny’s model is the “quasi-program.” He rejected the idea that evolution directly programmed organisms to deteriorate and die at a predetermined age. Instead, he proposed that aging represents the unintended continuation of genetically regulated developmental programs. These programs are not “designed” to cause aging; they become damaging because evolution favored their early-life benefits without fully eliminating their late-life consequences. The theory therefore combines molecular mechanisms with evolutionary principles such as antagonistic pleiotropy, in which the same biological trait can improve fitness early in life while producing harmful effects later.

The hyperfunction theory challenges the traditional disposable soma model, which attributes aging primarily to limited investment in cellular maintenance and the gradual accumulation of molecular damage. The disposable soma framework emphasizes imperfect DNA repair, protein quality control, antioxidant defenses, and other forms of somatic preservation. Blagosklonny’s alternative does not deny that damage accumulates, but it places greater emphasis on the active biological signals that can accelerate dysfunction. In particular, excessive signaling through mTOR, growth hormone, and insulin-like growth factor 1, or IGF-1, may drive tissue changes that become increasingly pathological with age.

This reasoning also offers a mechanistic interpretation of several lifespan-extending interventions. Rapamycin, a drug that inhibits mTOR, has attracted major interest because experiments in laboratory animals have shown that it can extend lifespan and delay multiple age-related diseases. Caloric restriction, which reduces nutrient availability and alters insulin and IGF-1 signaling, has likewise been associated with longevity benefits in several organisms. From Blagosklonny’s perspective, these interventions may work not merely by slowing the accumulation of damage, but by reducing persistent growth signals that continue to push aging tissues toward dysfunction.

The authors emphasize that Blagosklonny’s influence extended beyond any single hypothesis. Through an exceptionally large body of theoretical writing and his editorial leadership, he encouraged researchers to connect findings that are often studied in isolation. His work prompted scientists to consider how cancer, cellular senescence, metabolism, development, and aging might be linked through shared signaling networks. The essay suggests that this integrative style of reasoning has helped stimulate continuing research into programmatic theories of aging, biological clocks, reproductive decline, and the late-life emergence of chronic disease.

Whether the hyperfunction theory becomes a universally accepted explanation of aging remains unresolved. Aging is biologically complex, and evidence supports contributions from genomic instability, mitochondrial dysfunction, inflammation, impaired protein homeostasis, stem-cell exhaustion, and altered intercellular communication, among other processes. Nevertheless, the theory has remained influential because it offers a testable explanation for why pathways that are indispensable in youth can become damaging in later life, and why interventions that restrain growth signaling may influence lifespan. The new essay concludes that, regardless of which elements ultimately enter the mainstream, Blagosklonny’s ideas have permanently shaped scientific discussion. His legacy lies not only in specific claims about aging, but also in his insistence that conceptual research—when grounded in evidence—can reveal connections that conventional experiments may overlook.

Subject of Research: Aging biology, biogerontology, hyperfunction theory, evolutionary physiology, and programmatic theories of aging

Article Title: Misha Blagosklonny: a life of ideas

News Publication Date: August 10, 2026

Web References: https://doi.org/10.18632/aging.206412; Aging, Volume 18; Mikhail Blagosklonny profile

References: Gems D, Demaria M. “Misha Blagosklonny: a life of ideas.” Aging. DOI: 10.18632/aging.206412.

Image Credits: Copyright © 2026 Gems and Demaria. Open access under the Creative Commons Attribution License (CC BY 4.0).

Keywords: aging, hyperfunction theory, mTOR, rapamycin, caloric restriction, cellular senescence, quasi-program, disposable soma, biogerontology, evolutionary physiology, Mikhail Blagosklonny

Published in Volume 18 of Aging on July 24, 2026, the article does not report new laboratory experiments. Instead, it traces the intellectual history of a theory that challenges the traditional view of aging as primarily the result of accumulated molecular damage. The conventional model emphasizes the gradual buildup of DNA mutations, oxidative stress, mitochondrial failure, damaged proteins, and other forms of cellular deterioration. The hyperfunction theory proposes that many age-related changes arise because biological systems designed to promote growth and development remain active—or become dysregulated—through adulthood.

The theory does not suggest that aging is deliberately programmed in the same way as an organism’s development. Rather, it describes aging as an unintended consequence of developmental programs that fail to shut down completely. During early life, signaling networks such as the insulin-like growth factor-1, or IGF-1, pathway and the mechanistic target of rapamycin, known as mTOR or TOR, stimulate cell growth, protein production, metabolism, and reproduction. These processes are essential in youth, but their continued activation later in life can promote inflammation, abnormal cell growth, loss of cellular balance, and declining tissue function.

The perspective follows the evolution of these ideas from nineteenth-century theories of aging to the work of Clive McCay, whose caloric-restriction experiments helped establish that lifespan could be altered by changing an organism’s nutritional environment. It also discusses George Williams’ theory of antagonistic pleiotropy, which proposed that genes beneficial early in life could produce harmful effects in old age. A gene that enhances growth or reproductive success before reproduction, for example, may be favored by natural selection even if the same activity contributes to disease decades later, when evolutionary pressure is weaker.

A central figure in the modern development of the hyperfunction theory was the late Mikhail Blagosklonny. He argued that aging could result from “quasi-programs,” biological processes that resemble programmed development but continue after their adaptive function has ended. In this model, aging is not an actively selected outcome, but a form of runaway or excessive biological activity. Persistent growth signaling could gradually shift tissues away from maintenance and repair, helping explain why aging is associated with conditions such as cancer, fibrosis, immune dysfunction, metabolic disease, and the progressive loss of regenerative capacity.

Several findings from animal research have increased interest in this framework. Single-gene interventions have extended lifespan in organisms ranging from worms to mice, demonstrating that aging is biologically modifiable rather than completely fixed. In mice, reduced growth hormone and IGF-1 signaling can delay multiple features of aging, while rapamycin, a drug that inhibits TOR signaling, has extended lifespan in several experimental settings. These interventions affect regulatory networks that control growth, metabolism, protein synthesis, and cellular recycling, suggesting that lifespan may be influenced by coordinated biological systems rather than only by the repair of isolated molecular lesions.

Caloric restriction is also presented as evidence that aging involves regulated mechanisms. Reducing calorie intake without causing malnutrition can extend lifespan in many laboratory organisms and alter insulin signaling, TOR activity, mitochondrial metabolism, inflammation, and stress resistance. Although the precise effects vary between species and experimental conditions, the intervention is difficult to explain as a simple reduction in random damage. Instead, it appears to activate a physiological state that prioritizes maintenance and survival over growth and reproduction. The author nevertheless stresses that molecular damage remains important, particularly in diseases such as cancer, and may interact continuously with programmatic mechanisms.

The perspective identifies partial cellular reprogramming as one of the most important future tests of the hyperfunction theory. Reprogramming techniques use defined factors to alter gene regulation and partially reset aspects of cellular age without fully converting mature cells into pluripotent stem cells. In principle, this approach could restore youthful patterns of gene expression, improve tissue repair, and reverse some age-associated dysfunction. However, the same pathways that increase plasticity and rejuvenation may also create risks, including uncontrolled proliferation and tumor formation. Developing tissue-specific reprogramming strategies could therefore be essential for separating beneficial rejuvenation from dangerous loss of cellular identity.

Magalhães concludes that no single theory is likely to explain every aspect of aging. Developmental programs, epigenetic changes, metabolic regulation, chronic inflammation, DNA damage, mitochondrial dysfunction, and protein quality control may all contribute, with their relative importance differing among tissues and diseases. The hyperfunction framework offers a way to connect evolutionary theory with experimental longevity research and may help identify interventions that restore biological balance rather than merely treating individual symptoms. The article argues that integrating developmental biology, genetics, epigenetics, and regenerative medicine could reveal why aging differs across species and how its most harmful processes might eventually be selectively modified.

Subject of Research: Aging biology and the hyperfunction theory of aging

Article Title: A Brief History of the Hyperfunction Theory of Aging and Future Directions

News Publication Date: August 6, 2026

Web References: https://doi.org/10.18632/aging.206403; Aging-US Volume 18

References: de Magalhães, J. P. “A Brief History of the Hyperfunction Theory of Aging and Future Directions.” Aging-US, published July 24, 2026. DOI: 10.18632/aging.206403

Keywords: aging, longevity, hyperfunction theory, programmatic aging, quasi-programs, antagonistic pleiotropy, caloric restriction, rapamycin, mTOR, IGF-1, cellular reprogramming